{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:28:29Z","timestamp":1790497709445,"version":"4.1.0"},"reference-count":46,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":3165,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,1]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>\n                                 <jats:bold>The predictive role of antinuclear antibodies (ANAs) remains elusive in the long-term outcome of primary biliary cirrhosis (PBC). The progression of PBC was evaluated in association with ANAs using stepwise Cox proportional hazard regression and an unconditional stepwise logistic regression model based on the data of 276 biopsy-proven, definite PBC patients who have been registered to the National Hospital Organization Study Group for Liver Disease in Japan (NHOSLJ). When death of hepatic failure\/liver transplantation (LT) was defined as an end-point, positive anti-gp210 antibodies (Hazard ratio (HR) = 6.742, 95% confidence interval (CI): 2.408, 18.877), the late stage (Scheuer's stage 3, 4) (HR = 4.285, 95% CI:1.682,10.913) and male sex (HR = 3.266, 95% CI: 1.321,8.075) were significant risk factors at the time of initial liver biopsy. When clinical progression to death of hepatic failure\/LT (i.e., hepatic failure type progression) or to the development of esophageal varices or hepatocellular carcinoma without developing jaundice (Total bilirubin &lt; 1.5 mg\/dL) (i.e., portal hypertension type progression) was defined as an end-point in the early stage (Scheuer's stage 1, 2) PBC patients, positive anti-gp210 antibodies was a significant risk factor for hepatic failure type progression [odds ratio (OR) = 33.777, 95% CI: 5.930, 636.745], whereas positive anti-centromere antibodies was a significant risk factor for portal hypertension type progression (OR = 4.202, 95% CI: 1.307, 14.763). Histologically, positive anti-gp210 antibodies was most significantly associated with more severe interface hepatitis and lobular inflammation, whereas positive anticentromere antibodies was most significantly associated with more severe ductular reaction.<\/jats:bold>\n                                 <jats:bold>\n                                    Conclusion:\n                                 <\/jats:bold>\n                                 <jats:bold>These results indicate 2 different progression types in PBC, hepatic failure type and portal hypertension type progression, which may be represented by positive-anti-gp210 and positive-anticentromere antibodies, respectively. (Hepatology 2007;45:118\u2013127.)<\/jats:bold>\n                              <\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.21472","type":"journal-article","created":{"date-parts":[[2006,12,22]],"date-time":"2006-12-22T23:17:23Z","timestamp":1166829443000},"page":"118-127","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":333,"title":["Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis"],"prefix":"10.1097","volume":"45","author":[{"given":"Minoru","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisayoshi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsumasa","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsumi","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Takii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Koyabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terufumi","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Daikoku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seigo","family":"Abiru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yatsuhashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiichi","family":"Takezaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohiko","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Sugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuji","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Saoshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideharu","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Sodeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeki","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihide","family":"Masumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takehiro","family":"Sando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyokichi","family":"Muro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakera","family":"Shums","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary L.","family":"Norman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Ishibashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-17-20241202","first-page":"387","article-title":"Primary biliary cirrhosis.","volume":"46","author":"Rubin","year":"1965","journal-title":"Am J Pathol"},{"key":"R2-17-20241202","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptoms progression in a geographically based cohort of patients with primary biliary cirrhosis: followup to 28 years.","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"key":"R3-17-20241202","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1055\/s-2007-1007183","article-title":"Antimitochondrial antibodies in primary biliary cirrhosis.","volume":"17","author":"Leung","year":"1997","journal-title":"Semin Liver Dis"},{"key":"R4-17-20241202","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1055\/s-2007-1007185","article-title":"Nuclear envelope protein autoantibodies in primary biliary cirrhosis.","volume":"17","author":"Courvalin","year":"1997","journal-title":"Semin Liver Dis"},{"key":"R5-17-20241202","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-2005-916321","article-title":"Antinuclear antibodies in primary biliary cirrhosis.","volume":"25","author":"Invernizzi","year":"2005","journal-title":"Semin Liver Dis"},{"key":"R6-17-20241202","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1136\/gut.2003.036558","article-title":"Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis.","volume":"54","author":"Rigopoulou","year":"2005","journal-title":"Gut"},{"key":"R7-17-20241202","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1440-1746.1998.01553.x","article-title":"Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis.","volume":"13","author":"Itoh","year":"1998","journal-title":"J Gastroenterol Hepatol"},{"key":"R8-17-20241202","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0168-8278(00)00040-4","article-title":"Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis.","volume":"34","author":"Invernizzi","year":"2001","journal-title":"J Hepatol"},{"key":"R9-17-20241202","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1572-0241.2003.07257.x","article-title":"Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis.","volume":"98","author":"Muratori","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R10-17-20241202","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0896-8411(03)00033-7","article-title":"Profile and clinical significance of antinuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study.","volume":"20","author":"Miyachi","year":"2003","journal-title":"J Autoimmun"},{"key":"R11-17-20241202","first-page":"1123","article-title":"Prevalence, kinetics, and therapeutic modulation of autoantibodies against Sp100 and promyelocytic leukemia protein in a large cohort of patients with primary biliary cirrhosis.","volume":"26","author":"Zuchner","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R12-17-20241202","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jhep.2004.11.016","article-title":"Antibody titer to gp210C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis.","volume":"42","author":"Nakamura","year":"2005","journal-title":"J Hepatol"},{"key":"R13-17-20241202","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1542-3565(04)00465-3","article-title":"Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure.","volume":"2","author":"Yang","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R14-17-20241202","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/hep.21172","article-title":"Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis.","volume":"43","author":"WesierskaGadek","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R15-17-20241202","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1440-1746.1995.tb01597.x","article-title":"High prevalence of antibodies to recombinant CENPB in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities.","volume":"10","author":"Parveen","year":"1995","journal-title":"J Gastroenterol Hepatol"},{"key":"R16-17-20241202","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/gut.2005.075002","article-title":"Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis.","volume":"55","author":"Rigamonti","year":"2006","journal-title":"Gut"},{"key":"R17-17-20241202","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1016\/S0140-6736(04)16154-0","article-title":"Autoantibodies as predictors of disease.","volume":"363","author":"Scofield","year":"2004","journal-title":"Lancet"},{"key":"R18-17-20241202","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.2337\/diabetes.54.suppl_2.S52","article-title":"Autoantibodies in diabetes.","volume":"54","author":"Pihoker","year":"2005","journal-title":"Diabetes"},{"key":"R19-17-20241202","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/art.20044","article-title":"Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study.","volume":"50","author":"van Gaalen","year":"2004","journal-title":"Arthritis Rheum"},{"key":"R20-17-20241202","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus.","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"key":"R21-17-20241202","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1572-0241.2006.00468.x","article-title":"Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohns disease patients.","volume":"101","author":"Amre","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R22-17-20241202","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/hep.510290444","article-title":"Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression.","volume":"29","author":"Degott","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R23-17-20241202","first-page":"1257","article-title":"Primary biliary cirrhosis.","volume":"60","author":"Scheuer","year":"1967","journal-title":"Proc R Soc Med"},{"key":"R24-17-20241202","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jaut.2005.10.007","article-title":"Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis.","volume":"26","author":"Nakamura","year":"2006","journal-title":"J Autoimmun"},{"key":"R25-17-20241202","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/art.1780230602","article-title":"Diversity of antinuclear antibodies in progressive systemic sclerosis: anticentromere antibody and its relationship to CREST syndrome.","volume":"23","author":"Tan","year":"1980","journal-title":"Arthritis Rheum"},{"key":"R26-17-20241202","first-page":"1488","article-title":"Clinical and serological heterogeneity in patients with anticentromere antibodies.","volume":"32","author":"Miyawaki","year":"2005","journal-title":"J Rheumatol"},{"key":"R27-17-20241202","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1399-3038.2000.00066.x","article-title":"Anticentromere antibodies as a marker of Raynauds phenomenon in pediatric rheumatologic diseases.","volume":"11","author":"Hossny","year":"2000","journal-title":"Pediatr Allergy Immunol"},{"key":"R28-17-20241202","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.1780260714","article-title":"Anticentromere antibodies in primary biliary cirrhosis.","volume":"26","author":"Makinen","year":"1983","journal-title":"Arthritis Rheum"},{"key":"R29-17-20241202","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1136\/ard.60.11.1046","article-title":"Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients.","volume":"60","author":"Marasini","year":"2001","journal-title":"Ann Rheuma Dis"},{"key":"R30-17-20241202","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1568-9972(02)00083-6","article-title":"Antichromatin (antinucleosome) autoantibodies.","volume":"1","author":"Burlingame","year":"2002","journal-title":"Autoimmun Rev"},{"key":"R31-17-20241202","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/0016-5085(85)90001-0","article-title":"Sequential and diagnostic features in primary biliary cirrhosis based on serial histologic study in 209 patients.","volume":"88","author":"Portmann","year":"1985","journal-title":"Gastroenterology"},{"key":"R32-17-20241202","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0168-8278(99)80098-1","article-title":"Poupon RE, and the UDCAPBC Group. Clinical and biochemical expression of the histopathological lesions of primary biliary cirrhosis.","volume":"30","author":"Poupon","year":"1999","journal-title":"J Hepatol"},{"key":"R33-17-20241202","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1053\/gast.2002.31880","article-title":"Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodioltreated patients.","volume":"122","author":"Corpechot","year":"2002","journal-title":"Gastroenterology"},{"key":"R34-17-20241202","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0168-8278(03)00192-2","article-title":"Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis.","volume":"39","author":"Poupon","year":"2003","journal-title":"J Hepatol"},{"key":"R35-17-20241202","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis.","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"key":"R36-17-20241202","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/hep.20650","article-title":"Fibrosis correlates with a ductular reaction in hepatitis C: Roles of impaired replication, progenitor cells and steatosis.","volume":"41","author":"Clouston","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R37-17-20241202","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1053\/j.gastro.2004.08.006","article-title":"The cholangiopathies: disorders of biliary epithelia.","volume":"127","author":"Lazaridis","year":"2004","journal-title":"Gastroenterology"},{"key":"R38-17-20241202","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1582-4934.2006.tb00292.x","article-title":"Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF as major players and therapeutic targets.","volume":"10","author":"Gressner","year":"2006","journal-title":"J Cell Mol Med"},{"key":"R39-17-20241202","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1172\/JCI116504","article-title":"Molecular mimicry in primary biliary cirrhosis: evidence for biliary epithelial expression of a molecule crossreactive with pyruvate dehydrogenase complexE2.","volume":"91","author":"Van de Water","year":"1993","journal-title":"J Clin Invest"},{"key":"R40-17-20241202","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.4049\/jimmunol.149.12.4067","article-title":"Interferon enhance expression of SP100, an autoantigen in primary biliary cirrhosis.","volume":"149","author":"Guldner","year":"1992","journal-title":"J Immunol"},{"key":"R41-17-20241202","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1034\/j.1600-065X.2003.00042.x","article-title":"Apoptosis, tolerance, and regulatory T cells: old wine, new wineskins.","volume":"193","author":"Ferguson","year":"2003","journal-title":"Immunol Rev"},{"key":"R42-17-20241202","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/hep.510260604","article-title":"Enhanced apoptosis relates to bile duct loss in primary biliary cirrhosis.","volume":"26","author":"Harada","year":"1997","journal-title":"HEPATOLOGY"},{"key":"R43-17-20241202","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.autrev.2004.08.038","article-title":"Proteosomal processing of nuclear autoantigens in systemic autoimmunity.","volume":"4","author":"Chen","year":"2005","journal-title":"Autoimmun Rev"},{"key":"R44-17-20241202","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1084\/jem.181.5.1835","article-title":"HLA DRB4 0101restricted immunodominant Tcell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases.","volume":"181","author":"Shimoda","year":"1995","journal-title":"J Exp Med"},{"key":"R45-17-20241202","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1053\/jhep.2000.18714","article-title":"Fine specificity of T cells reactive to human PDCE2 163176 peptide, the immunodominant autoantigen in primary biliary cirrhosis: implications for molecular mimicry and crossrecognition among mitochondrial autoantigens.","volume":"32","author":"Shigematsu","year":"2000","journal-title":"HEPATOLOGY"},{"key":"R46-17-20241202","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0016-5085(03)00387-1","article-title":"Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis.","volume":"124","author":"Shimoda","year":"2003","journal-title":"Gastroenterology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.21472","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-200701000-00017","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T16:08:04Z","timestamp":1733155684000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-200701000-00017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.21472","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2007,1]]}}}